Skip to main content

Advertisement

Fig. 5 | BMC Neurology

Fig. 5

From: Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1

Fig. 5

Proportion of patients with no evidence of clinical disease activity. Based on (a) absence of all protocol-defined relapses, (b) absence of Scripps-assessed moderate and/or severe relapses, or (c) absence of severe relapses, at 1 year. Based on a logistic model adjusting for age (< 40 vs. ≥40 years), sex, baseline EDSS (≤3.5 vs. > 3.5), number of relapses in 2 years prior to screening, and time since MS onset. Values within parentheses are 95% CI values. aDefined as no relapses and no 3-month confirmed disability progression (1-point increase in EDSS score if the baseline EDSS score was < 6.0 or 0.5-point increase if the baseline EDSS score was ≥6.0). (EDSS score could be > 5 if scores increase between screening and baseline.) bDefined as no relapses and no 3-month confirmed disability progression (1-point increase in EDSS score if the baseline EDSS score was < 6.0 or 0.5-point increase if the baseline EDSS score was ≥6.0). (EDSS score could be > 5 if scores increase between screening and baseline.) Relapses are defined as Scripps-assessed moderate and/or severe. cDefined as no relapses and no 3-month confirmed disability progression (1-point increase in EDSS score if the baseline EDSS score was < 6.0 or 0.5-point increase if the baseline EDSS score was ≥6.0). (EDSS score could be > 5 if scores increase between screening and baseline.) Relapses are defined as Scripps-assessed severe. EDSS: Expanded Disability Status Scale; IFN β-1a: interferon beta-1a; OR: odds ratio; SC: subcutaneously; tiw: three times weekly

Back to article page